Masi, A
Lampit, A
Glozier, N
Hickie, I B
Guastella, A J
Article History
Received: 12 June 2015
Revised: 4 August 2015
Accepted: 9 August 2015
First Online: 22 September 2015
Competing interests
: AL received in-kind research support in the form of no-cost software from BrainTrain and HAPPYneuron for projects unrelated to this work. IBH is a Commissioner in Australia’s National Mental Health Commission. He has led projects for health professionals and the community supported by governmental, community agency and pharmaceutical industry partners (Wyeth, Eli Lily, Servier, Pfizer and AstraZeneca) for the identification and management of depression and anxiety. He has received honoraria for presentations of his own work at educational seminars supported by a number of non-government organizations and the pharmaceutical industry (including Servier, Pfizer, AstraZeneca and Eli Lilly). He is a member of the Medical Advisory Panel for Medibank Private and also a Board Member of Psychosis Australia Trust. He leads an investigator-initiated study of the effects of agomelatine on circadian parameters (supported in part by Servier) and has participated in a multicentre clinical trial of the effects of agomelatine on sleep architecture in depression and a Servier-supported study of major depression and sleep disturbance in primary care settings. AL is funded by a NHMRC Project Grant (ID 1084880), IBH is funded by an NHMRC Research Fellowship (APP 1046899) and AJG is funded by a NHMRC career development fellowship (APP1061922) and project grant (1043664). The remaining authors declare no conflict of interest.